Develops complement inhibition therapies to treat a broad range of debilitating diseases, including rare and chronic conditions.
Apellis Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on advancing therapeutic compounds that target the complement system to address autoimmune and inflammatory diseases. Established in 2009 and headquartered in Waltham, Massachusetts, Apellis Pharmaceuticals specializes in the discovery, development, and commercialization of innovative treatments. At present, the company's flagship product, EMPAVELI, is approved for multiple indications including paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, and certain types of glomerulonephritis. EMPAVELI also shows promise in treating amyotrophic lateral sclerosis and thrombotic microangiopathy associated with hematopoietic stem cell transplantation.
Apellis Pharmaceuticals also offers SYFOVRE for the treatment of geographic atrophy, a severe form of age-related macular degeneration. The company's robust pipeline includes APL-2006, a bispecific inhibitor targeting both C3 and VEGF for wet age-related macular degeneration and geographic atrophy, and APL-1030, a C3 inhibitor aimed at various neurodegenerative diseases. Moreover, Apellis Pharmaceuticals is exploring combinations of EMPAVELI with small interfering RNA to reduce C3 protein production in the liver, highlighting their commitment to advancing novel therapeutic approaches.
In addition to its internal research and development efforts, Apellis Pharmaceuticals has established strategic collaborations, including a partnership with Swedish Orphan Biovitrum AB for the development and commercialization of pegcetacoplan. Furthermore, a collaboration with Beam Therapeutics Inc. focuses on leveraging Beam's base editing technology to discover new treatments for complement-driven diseases. Through these initiatives, Apellis Pharmaceuticals continues to expand its impact in the biopharmaceutical industry by advancing transformative therapies for patients with significant unmet medical needs.